Deltex Medical Group plc
LSE: DEMG.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Andrew Jonathan Mears
- Employees
- 24
- Headquarters
- Chichester, United Kingdom
- IPO year
- 2001
- Market cap
- £663.6K
- Website
- https://www.deltexmedical.com
Loading DEMG…
Loading profile data…Frequently asked questions about DEMG
What does Deltex Medical Group plc (DEMG.L) do?
Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally. It offers esophageal Doppler Probes that is used to measure a patient's central vascular blood flow and...
Where does DEMG.L trade?
Deltex Medical Group plc (DEMG.L) trades on the London Stock Exchange.
What sector is DEMG.L in?
Deltex Medical Group plc (DEMG.L) operates in the Healthcare sector, specifically in the Medical - Devices industry.
Who is the CEO of Deltex Medical Group plc?
Andrew Jonathan Mears is the chief executive officer of Deltex Medical Group plc (DEMG.L).
Where is Deltex Medical Group plc headquartered?
Deltex Medical Group plc is headquartered in United Kingdom.
Does DEMG.L pay a dividend?
Deltex Medical Group plc (DEMG.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DEMG.L go public?
Deltex Medical Group plc (DEMG.L) completed its initial public offering in 2001.